<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Induction of general anesthesia: Overview
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Induction of general anesthesia: Overview
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Induction of general anesthesia: Overview
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Adam King, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            William Benedetto, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alexandra Plichta, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Girish P Joshi, MB, BS, MD, FFARCSI
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Nancy A Nussmeier, MD, FAHA
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Aug 18, 2022.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H3717294066">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         General anesthesia establishes a reversible state that includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hypnosis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Amnesia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Analgesia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Akinesia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autonomic and sensory block
        </p>
        <p>
        </p>
        <p>
         The goals for induction of general anesthesia are to rapidly, safely, and pleasantly produce these conditions while maintaining adequate oxygenation, ventilation, and hemodynamic stability. This topic provides an overview of preinduction preparations and selection of anesthetic induction agents and techniques. Recommendations for specific types of surgical procedures and for patients with specific comorbidities are discussed in individual topics.
        </p>
        <p>
         Specific intravenous (IV) and inhalation anesthetics and neuromuscular blocking agents used during induction of general anesthesia are reviewed in separate topics:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         IV induction and adjuvant agents (see
         <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">
          "General anesthesia: Intravenous induction agents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94536.html" rel="external">
          "Perioperative uses of intravenous opioids in adults: General considerations", section on 'Induction'
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inhalation agents (see
         <a class="medical medical_review" href="/z/d/html/114826.html" rel="external">
          "Inhalation anesthetic agents: Clinical effects and uses", section on 'Induction of general anesthesia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94534.html" rel="external">
          "Inhalation anesthetic agents: Properties and delivery"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Neuromuscular blocking agents (see
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia"
         </a>
         )
        </p>
        <p>
        </p>
        <p>
         Techniques used during induction of general anesthesia (eg, preoxygenation, airway management) are also reviewed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/113243.html" rel="external">
          "Preoxygenation and apneic oxygenation for airway management for anesthesia"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/91218.html" rel="external">
          "Airway management for induction of general anesthesia"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/94214.html" rel="external">
          "Rapid sequence induction and intubation (RSII) for anesthesia"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/90615.html" rel="external">
          "Management of the difficult airway for general anesthesia in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2107374177">
         <span class="h1">
          CONTINUUM OF SEDATION DURING ANESTHETIC INDUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Anesthetic agents demonstrate a dose-response effect, with progressively higher doses providing progressively deeper levels of sedation and anesthesia. During induction of general anesthesia, sedation progresses as a continuum of effect rather than as a consecutive series of distinct states with clear transitions  (
         <a class="graphic graphic_table graphicRef109909" href="/z/d/graphic/109909.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid1">
          1
         </a>
         ].
        </p>
        <p>
         Light/minimal sedation with anxiolysis and analgesia is a level in which responsiveness to voice, airway patency, spontaneous ventilation, and cardiovascular function are preserved. Moderate sedation, also termed conscious sedation, represents a deeper level of sedation and analgesia, in which the patient remains responsive to voice, has intact airway patency and spontaneous ventilation, but may have reduced blood pressure. Deep sedation is a state in which the patient no longer responds to voice, and may have compromised airway patency, ventilation, and cardiovascular function. However, movement in response to a noxious surgical stimulus still occurs. General anesthesia is an anesthetic depth at which the patient will not respond to voice or to noxious surgical stimuli.
        </p>
        <p>
         As the patient progresses through deeper planes ("stages") of anesthesia, airway reflexes and patency, spontaneous ventilation, cardiovascular function, and muscle tone become increasingly depressed  (
         <a class="graphic graphic_figure graphicRef113985" href="/z/d/graphic/113985.html" rel="external">
          figure 1
         </a>
         ). Patients may rapidly transition from one stage of anesthetic depth to the next. Thus, urgent interventions may become necessary to manage the airway or support respiratory and cardiovascular functions. For example, during "Stage 2," of general anesthesia (ie, the "reactive stage"), the patient is prone to laryngospasm requiring rapid intervention. During deeper states of general anesthesia, over-dosing of sedative/hypnotics may cause hypotension and cardiovascular collapse.
        </p>
        <p>
         Some degree of resistance to changes in consciousness typically occurs during induction of general anesthesia such that a higher effect-site concentration of anesthetic agent may be necessary to achieve loss of consciousness compared with the concentration noted upon return of consciousness during emergence [
         <a href="#rid2">
          2-4
         </a>
         ]. This phenomenon is termed hysteresis or "neural inertia." (See
         <a class="medical medical_review" href="/z/d/html/94537.html" rel="external">
          "Emergence from general anesthesia"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H254392428">
         <span class="h1">
          PREPARATION FOR ANESTHETIC INDUCTION
         </span>
        </p>
        <p class="headingAnchor" id="H1788937456">
         <span class="h2">
          Before patient arrival
         </span>
         <span class="headingEndMark">
          —
         </span>
         Before patient arrival in the operating room (OR) or interventional suite, the following steps are necessary:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Anesthesia machine checkout
         </strong>
         – The anesthesia machine checkout should be performed prior to the patient's arrival in the operating room  (
         <a class="graphic graphic_table graphicRef101563" href="/z/d/graphic/101563.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid5">
          5
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/94594.html" rel="external">
          "Anesthesia machines: Prevention, diagnosis, and management of malfunctions"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Airway equipment preparation
         </strong>
         – Since all anesthetic induction agents and adjuvants may cause respiratory depression, preparations for advanced airway management are necessary. (See
         <a class="medical medical_review" href="/z/d/html/91218.html" rel="external">
          "Airway management for induction of general anesthesia", section on 'Preparation for induction of anesthesia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Drug preparation
         </strong>
         – Routinely administered anesthetic drugs should be prepared. Drugs for treatment of common complications and emergencies should be immediately available. These include but are not limited to:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A sedative/hypnotic, most commonly
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         ;
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          etomidate
         </a>
         or
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         can be selected for hemodynamically unstable patients. (See
         <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">
          "General anesthesia: Intravenous induction agents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A neuromuscular blocking agent (NMBA), either a nondepolarizing agent (eg,
         <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">
          rocuronium
         </a>
         ,
         <a class="drug drug_general" data-topicid="10041" href="/z/d/drug information/10041.html" rel="external">
          vecuronium
         </a>
         ) or a depolarizing agent (
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          succinylcholine
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A vasopressor, most commonly
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         .
         <strong>
         </strong>
         Alternatives include
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         or dilute
         <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">
          norepinephrine
         </a>
         as appropriate  (
         <a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">
          table 3
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         An anticholinergic (
         <a class="drug drug_general" data-topicid="8983" href="/z/d/drug information/8983.html" rel="external">
          atropine
         </a>
         or
         <a class="drug drug_general" data-topicid="8496" href="/z/d/drug information/8496.html" rel="external">
          glycopyrrolate
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2417514694">
         <span class="h2">
          After patient arrival
         </span>
         <span class="headingEndMark">
          —
         </span>
         After patient arrival in the OR, the following steps are completed:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Monitoring
         </strong>
         – In addition to continuous personal observation provided by the anesthesia provider, the patient should be connected to standard American Society of Anesthesiologists (ASA) monitors before induction of general anesthesia [
         <a href="#rid6">
          6
         </a>
         ]. Standard monitors include but are not limited to: electrocardiogram (ECG), pulse oximetry, blood pressure (BP), and temperature monitors, as well as an oxygen (O
         <sub>
          2
         </sub>
         ) analyzer and a continuous end-tidal carbon dioxide (ETCO
         <sub>
          2
         </sub>
         ) analyzer (eg, capnography, capnometry, or mass spectroscopy) in the patient breathing system  (
         <a class="graphic graphic_table graphicRef110080" href="/z/d/graphic/110080.html" rel="external">
          table 4
         </a>
         ). Preinduction measurements are obtained to ensure proper functioning of the monitors and to establish the patient's baseline values. (See
         <a class="medical medical_review" href="/z/d/html/100067.html" rel="external">
          "Basic patient monitoring during anesthesia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intravenous access
         </strong>
         – Virtually all adult patients have at least one peripheral venous or other vascular access catheter placed before induction. Catheters should be checked to ensure that they are patent. Intravenous (IV) fluids and equipment to obtain additional venous access should be immediately available. (See
         <a class="medical medical_review" href="/z/d/html/13824.html" rel="external">
          "Peripheral venous access in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preprocedure checklist
         </strong>
         – An appropriate preprocedure checklist should be completed; an example is provided in the table  (
         <a class="graphic graphic_table graphicRef52392" href="/z/d/graphic/52392.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/15077.html" rel="external">
          "Patient safety in the operating room", section on 'Timeouts, briefing, and debriefing'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2134519527">
         <span class="h2">
          Immediately before induction
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Positioning for induction
         </strong>
         – Before induction of anesthesia, the patient's head is positioned in the sniffing position for optimal airway management (atlanto-occipital extension with head elevation of 3 to 7 cm) [
         <a href="#rid7">
          7
         </a>
         ], supported so that the neck is flexed and the head extended (assuming an absence of cervical spine pathology). If not contraindicated, the head of the bed is elevated 20 to 30 degrees. (See
         <a class="medical medical_review" href="/z/d/html/91218.html" rel="external">
          "Airway management for induction of general anesthesia", section on 'Patient positioning'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preoxygenation (denitrogenation
         </strong>
         ) – Before administration of any anesthetic induction or adjuvant agents, the patient is preoxygenated (denitrogenated) with 100 percent O
         <sub>
          2
         </sub>
         to increase O
         <sub>
          2
         </sub>
         reserve, thereby providing additional time to secure the airway [
         <a href="#rid8">
          8,9
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/91218.html" rel="external">
          "Airway management for induction of general anesthesia", section on 'Preoxygenation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H295889468">
         <span class="h1">
          SELECTION OF INDUCTION TECHNIQUE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Induction of general anesthesia may be accomplished using primarily intravenous (IV) or primarily inhalation anesthetic agents. Most adults prefer induction primarily with IV agents. (See
         <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">
          "General anesthesia: Intravenous induction agents"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/114826.html" rel="external">
          "Inhalation anesthetic agents: Clinical effects and uses", section on 'Induction of general anesthesia'
         </a>
         .)
        </p>
        <p>
         Notably, adults may be less satisfied with a primary inhalation induction technique compared with IV induction due to the unpleasant odor of anesthetic gases [
         <a href="#rid10">
          10
         </a>
         ], as well as a higher incidence of postoperative nausea and vomiting compared with use of IV agents such as
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         (see
         <a class="medical medical_review" href="/z/d/html/16849.html" rel="external">
          "Postoperative nausea and vomiting", section on 'Anesthetic factors'
         </a>
         ) [
         <a href="#rid10">
          10-12
         </a>
         ]. Furthermore, inhalation induction time is longer compared with IV induction. Several minutes of ventilation may be required. Thus, this technique is unsuitable for rapid sequence induction and intubation (RSII). (See
         <a class="medical medical_review" href="/z/d/html/94214.html" rel="external">
          "Rapid sequence induction and intubation (RSII) for anesthesia"
         </a>
         .)
        </p>
        <p>
         The ideal induction agent has a rapid onset of action, minimal cardiopulmonary or other side effects, and is cleared from the bloodstream quickly so that recovery is rapid. However, none of the available induction agents is ideal for all patients, and all have side effects. We typically administer combinations of agents from different pharmacologic classes during induction and/or maintenance of general anesthesia. This strategy minimizes the total dose of any one anesthetic agent, thereby reducing the incidence of undesirable side effects. Age and coexisting diseases affect selection and dosing of anesthetic induction and adjuvant agents. (See
         <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">
          "General anesthesia: Intravenous induction agents", section on 'Dosing considerations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/114826.html" rel="external">
          "Inhalation anesthetic agents: Clinical effects and uses", section on 'Influence of patient-related factors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H295889145">
         <span class="h1">
          INTRAVENOUS ANESTHETIC INDUCTION
         </span>
        </p>
        <p class="headingAnchor" id="H1728954157">
         <span class="h2">
          Patient selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         Adult patients usually have intravenous (IV) access and typically prefer induction with IV agents.
        </p>
        <p class="headingAnchor" id="H3160713997">
         <span class="h2">
          Techniques and anesthetic agents
         </span>
        </p>
        <p class="headingAnchor" id="H2602830616">
         <span class="h3">
          Induction with endotracheal intubation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Selection and dosing of sedative-hypnotic and adjuvant agents are determined by patient-specific factors, including age and comorbidities. (See
         <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">
          "General anesthesia: Intravenous induction agents", section on 'Dosing considerations'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intravenous sedative-hypnotic agent
         </strong>
         – During IV induction with planned endotracheal intubation, a primary IV sedative-hypnotic induction agent is typically administered  (
         <a class="graphic graphic_table graphicRef102350" href="/z/d/graphic/102350.html" rel="external">
          table 6
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">
          "General anesthesia: Intravenous induction agents"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intravenous adjuvant agents
         </strong>
         – One or more adjuvant IV agents (eg, short-acting opioid,
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         (
         <a class="graphic graphic_table graphicRef106541" href="/z/d/graphic/106541.html" rel="external">
          table 7
         </a>
         )) are also typically administered during induction to blunt the sympathetic stress response and cough reflex during laryngoscopy and intubation, minimize pain due to injection of the anesthetic induction agents, and supplement effects of the primary sedative-hypnotic anesthetic and reduce their dose. As an example, a reasonable combination of adjuvant agents is
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         25 to 100 mcg, followed by lidocaine 50 to 100 mg, with both administered immediately prior to induction when either
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         or
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          etomidate
         </a>
         is selected for the sedative-hypnotic induction agent. We start with the lower end of these dose ranges in patients with conditions such as advanced age and/or frailty; hemodynamic abnormalities caused by persistent bleeding or other factors resulting in hypovolemia, vasodilation, or myocardial dysfunction; or impaired renal or hepatic function. (See
         <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">
          "General anesthesia: Intravenous induction agents", section on 'Adjuvant agents'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">
          "General anesthesia: Intravenous induction agents", section on 'Dosing considerations'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         However, scant evidence is available to support use of any particular combination of agents. Notably, coadministration of agents acting on different receptor types may produce synergistic anesthetic effects. Thus, avoiding use of multiple agents or reducing doses may be prudent in older patients or those with significant comorbidities, particularly impaired renal and/or hepatic function. Adjuvant agents are typically avoided altogether in patients with actual or potential hemodynamic instability.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Neuromuscular blocking agent
         </strong>
         – A neuromuscular blocking agent (NMBA) is usually administered before endotracheal intubation  (
         <a class="graphic graphic_table graphicRef114271" href="/z/d/graphic/114271.html" rel="external">
          table 8
         </a>
         ). (See
         <a class="local">
          'Neuromuscular blocking agents'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia", section on 'Endotracheal intubation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Addition of an inhalation agent
         </strong>
         – Inhalation anesthetic agent(s) are often added shortly after initial loss of consciousness is achieved using IV agents. Administration of inhalation anesthetic(s) deepens anesthesia and blunts airway reflexes and sympathetic stress responses during laryngoscopy. Potent volatile inhalation agents also induce a dose-dependent decrease in skeletal muscle tone, which improves conditions during insertion of either an endotracheal tube or supraglottic airway. (See
         <a class="medical medical_review" href="/z/d/html/114826.html" rel="external">
          "Inhalation anesthetic agents: Clinical effects and uses", section on 'Use as a supplement (all inhalation agents)'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1691645889">
         <span class="h3">
          Induction with supraglottic airway placement
         </span>
         <span class="headingEndMark">
          —
         </span>
         During IV induction with planned insertion of a supraglottic airway (SGA) such as a laryngeal mask airway (LMA), an adequate depth is necessary to avoid coughing, gagging, breath-holding, laryngospasm, or bronchospasm. (See
         <a class="medical medical_review" href="/z/d/html/98733.html" rel="external">
          "Supraglottic devices (including laryngeal mask airways) for airway management for anesthesia in adults", section on 'Placement technique'
         </a>
         .)
        </p>
        <p>
         Similar to induction with planned endotracheal intubation (see
         <a class="local">
          'Induction with endotracheal intubation'
         </a>
         above),
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         is typically administered before the selected primary IV sedative-hypnotic induction agent [
         <a href="#rid13">
          13
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/94533.html" rel="external">
          "General anesthesia: Intravenous induction agents"
         </a>
         .)
        </p>
        <p>
         However, opioids may be avoided or minimized during the induction sequence if spontaneous ventilation is planned after SGA insertion to avoid a period of apnea due to opioid-induced respiratory depression. (See
         <a class="medical medical_review" href="/z/d/html/98733.html" rel="external">
          "Supraglottic devices (including laryngeal mask airways) for airway management for anesthesia in adults", section on 'Choice of mode of ventilation'
         </a>
         .)
        </p>
        <p>
         If difficulties are encountered with SGA placement or initial ventilation, additional doses of the selected sedative-hypnotic agent can be administered. Alternatively, intubation with an endotracheal tube can be performed. (See
         <a class="medical medical_review" href="/z/d/html/98733.html" rel="external">
          "Supraglottic devices (including laryngeal mask airways) for airway management for anesthesia in adults", section on 'Troubleshooting'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H295889239">
         <span class="h1">
          INHALATION ANESTHETIC INDUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Properties, mechanisms of action, and delivery of inhalation agents are discussed separately  (
         <a class="graphic graphic_table graphicRef113972" href="/z/d/graphic/113972.html" rel="external">
          table 9
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/94534.html" rel="external">
          "Inhalation anesthetic agents: Properties and delivery"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2146537383">
         <span class="h2">
          Patient selection
         </span>
         <span class="headingEndMark">
          —
         </span>
         An inhalation induction technique is often selected for younger pediatric patients or those with developmental delay to avoid fear of needles and responses to the pain of a needle stick [
         <a href="#rid14">
          14
         </a>
         ]. Inhalation induction may also be the preferred method for adult patients when:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Maintenance of spontaneous ventilation is desirable during induction. Examples include patients with intraoral, pharyngeal, or mediastinal mass causing compression of the airway if an awake intubation technique is not feasible.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An in situ tracheostomy is present since unpleasant odor and irritation of the airway are not problematic.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intravenous (IV) access is difficult to obtain. However, IV access should be established immediately after induction so that common problems such as hypotension during induction can be treated.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1908337494">
         <span class="h2">
          Techniques and specific inhalation agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inhalation induction of anesthesia requires a high concentration of a volatile anesthetic agent, with or without
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          nitrous oxide
         </a>
         (N
         <sub>
          2
         </sub>
         O). Development of non-pungent, nonirritant volatile anesthetics that have rapid onset (eg,
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          sevoflurane
         </a>
         ) has made inhalation induction of anesthesia via facemask less irritating and viable option compared with induction using older inhalation agents [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
         Modified administration techniques can be used to facilitate the speed of anesthetic induction. For example, the breathing circuit may be primed with a high
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          sevoflurane
         </a>
         concentration (eg, 8 percent) plus N
         <sub>
          2
         </sub>
         O. Then the patient is instructed to take a vital capacity breath (defined as a complete expiration followed by a complete inspiration), followed by a period of apnea with inflated lungs (ie, "breath-holding") [
         <a href="#rid15">
          15
         </a>
         ]. Typically this single breath technique achieves the 2 percent alveolar sevoflurane concentration required to tolerate painful interventions such as surgical incision [
         <a href="#rid16">
          16
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/94534.html" rel="external">
          "Inhalation anesthetic agents: Properties and delivery", section on 'Technique-related considerations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3659780157">
         <span class="h3">
          Potent volatile agents
         </span>
         <span class="headingEndMark">
          —
         </span>
         Advantages shared by all potent volatile anesthetic agents during induction of general anesthesia include excellent bronchodilation, dose-dependent decrease in skeletal muscle tone, and decrease in cerebral metabolic rate of oxygen consumption (CMRO
         <sub>
          2
         </sub>
         ). Disadvantages of these agents include respiratory depression, systemic vasodilation, and decreased blood pressure (BP), adverse effects which are dose-dependent. In rare instances, all potent volatile agents can precipitate malignant hyperthermia. (See
         <a class="medical medical_review" href="/z/d/html/114826.html" rel="external">
          "Inhalation anesthetic agents: Clinical effects and uses", section on 'Other clinical effects'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          Sevoflurane
         </a>
         <strong>
         </strong>
         – Sevoflurane has many characteristics of the ideal induction agent, and is the most commonly used potent volatile inhaled agent for this purpose. It has minimal odor, lacks pungency, and has potent bronchodilating characteristics [
         <a href="#rid10">
          10-12,14,17-19
         </a>
         ]. Furthermore, sevoflurane has relatively rapid onset due to its low tissue and blood solubilities, which also result in rapid clearance from the bloodstream and rapid recovery. The time to loss of consciousness may be as little as 60 seconds if a high concentration of sevoflurane (eg, 4 to 8 percent) is briefly delivered via a facemask [
         <a href="#rid14">
          14,15,20
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/114826.html" rel="external">
          "Inhalation anesthetic agents: Clinical effects and uses", section on 'Sevoflurane'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/114826.html" rel="external">
          "Inhalation anesthetic agents: Clinical effects and uses", section on 'Induction of general anesthesia'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8992" href="/z/d/drug information/8992.html" rel="external">
          Isoflurane
         </a>
         <strong>
         </strong>
         – Isoflurane is the most potent of the volatile anesthetics but is not ideal for use as the sole induction agent because of its relative pungency and slow onset (and recovery) compared with
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          sevoflurane
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/114826.html" rel="external">
          "Inhalation anesthetic agents: Clinical effects and uses", section on 'Isoflurane'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Halothane
         </strong>
         – Halothane is a sweet-smelling gas with only moderate pungency. However, halothane is no longer commercially available in North America due to adverse effects (particularly the possibility of halothane hepatitis). Also, halothane has the slowest onset compared with all other potent inhalation agents during induction of anesthesia because of its high tissue and blood solubility. Other disadvantages include significant myocardial depression at higher doses and risk of arrhythmias due to sensitization of the myocardium to catecholamines (either endogenous or exogenously administered
         <a class="drug drug_general" data-topicid="9409" href="/z/d/drug information/9409.html" rel="external">
          epinephrine
         </a>
         or
         <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">
          norepinephrine
         </a>
         ). For these reasons, newer inhalation agents such as
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          sevoflurane
         </a>
         have been developed to replace halothane. However, halothane is still used in many countries with limited resources for both induction and maintenance of general anesthesia due to its low cost and wide availability. (See
         <a class="medical medical_review" href="/z/d/html/114826.html" rel="external">
          "Inhalation anesthetic agents: Clinical effects and uses", section on 'Halothane'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8891" href="/z/d/drug information/8891.html" rel="external">
          Desflurane
         </a>
         <strong>
         </strong>
         – Desflurane is generally not used during induction of anesthesia via facemask. It is the most pungent of the volatile anesthetics and has the highest incidence of airway irritation (coughing, salivation, breath-holding, laryngospasm), particularly at high concentrations [
         <a href="#rid17">
          17,21
         </a>
         ]. Also, desflurane can cause sympathetic stimulation, tachycardia, and hypertension when administered in high or abruptly increased inspired concentrations. Since any inhalation agent must be rapidly increased to produce a high concentration during induction of general anesthesia in an awake patient, these properties limit use of desflurane during induction. (See
         <a class="medical medical_review" href="/z/d/html/114826.html" rel="external">
          "Inhalation anesthetic agents: Clinical effects and uses", section on 'Desflurane'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H163527534">
         <span class="h3">
          Nitrous oxide gas
         </span>
         <span class="headingEndMark">
          —
         </span>
         N
         <sub>
          2
         </sub>
         O is a sweet-smelling gas without pungency or potential for airway irritation. N
         <sub>
          2
         </sub>
         O increases speed of anesthetic onset if coadministered with any potent volatile inhalation agent, compared with administration of the potent agent alone, due to a phenomenon termed the "second gas" effect. Thus, it is often used as an adjuvant agent during inhalation induction of general anesthesia. (See
         <a class="medical medical_review" href="/z/d/html/94534.html" rel="external">
          "Inhalation anesthetic agents: Properties and delivery", section on 'Second gas effect'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/114826.html" rel="external">
          "Inhalation anesthetic agents: Clinical effects and uses", section on 'Nitrous oxide'
         </a>
         .)
        </p>
        <p>
         Notably, N
         <sub>
          2
         </sub>
         O is avoided during induction in certain patients, including those with pre-existing bowel distention, increased middle ear pressure, pneumothorax, pneumoperitoneum, pneumocephalus, intraocular gas, or venous air embolism [
         <a href="#rid22">
          22-24
         </a>
         ]. Further gaseous distension of such spaces during administration of N
         <sub>
          2
         </sub>
         O has potentially significant adverse consequences (eg, nausea with emesis, tension pneumothorax, increased intracranial pressure, vision loss, expansion of entrapped intravascular air). Also, N
         <sub>
          2
         </sub>
         O is typically avoided during induction in patients with cardiomyopathy and/or pulmonary hypertension because it causes mild myocardial depression and mild sympathetic nervous system stimulation that may increase pulmonary vascular resistance. (See
         <a class="medical medical_review" href="/z/d/html/114826.html" rel="external">
          "Inhalation anesthetic agents: Clinical effects and uses", section on 'Disadvantages and adverse effects'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2800567302">
         <span class="h1">
          NEUROMUSCULAR BLOCKING AGENTS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          For endotracheal intubation
         </strong>
         – During induction of general anesthesia, a neuromuscular blocking agent (NMBA) is usually administered to facilitate laryngoscopy and intubation if endotracheal intubation is planned  (
         <a class="graphic graphic_table graphicRef114271" href="/z/d/graphic/114271.html" rel="external">
          table 8
         </a>
         ). (See
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia", section on 'Endotracheal intubation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The choice of NMBA should be based on the desired speed of onset, reversibility, patient comorbidities, and anticipated difficulty of airway intubation. If rapid sequence intubation and induction is desired, either
         <a class="drug drug_general" data-topicid="9952" href="/z/d/drug information/9952.html" rel="external">
          succinylcholine
         </a>
         (SCh; 1 to 1.5 mg/kg) or
         <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">
          rocuronium
         </a>
         (1.2 mg/kg) is typically selected. If a relatively large dose of rocuronium is used to achieve swift onset of optimal intubating conditions, the neuromuscular blocking effect may be rapidly terminated by administering
         <a class="drug drug_general" data-topicid="105866" href="/z/d/drug information/105866.html" rel="external">
          sugammadex
         </a>
         16 mg/kg [
         <a href="#rid25">
          25,26
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/94214.html" rel="external">
          "Rapid sequence induction and intubation (RSII) for anesthesia", section on 'Neuromuscular blocking agents (NMBAs)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94535.html" rel="external">
          "Clinical use of neuromuscular blocking agents in anesthesia", section on 'Sugammadex'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Nondepolarizing NMBAs administered in usual doses (eg,
         <a class="drug drug_general" data-topicid="9872" href="/z/d/drug information/9872.html" rel="external">
          rocuronium
         </a>
         0.6 mg/kg,
         <a class="drug drug_general" data-topicid="10041" href="/z/d/drug information/10041.html" rel="external">
          vecuronium
         </a>
         ,
         <a class="drug drug_general" data-topicid="9270" href="/z/d/drug information/9270.html" rel="external">
          cisatracurium
         </a>
         ,
         <a class="drug drug_general" data-topicid="8973" href="/z/d/drug information/8973.html" rel="external">
          atracurium
         </a>
         , and
         <a class="drug drug_general" data-topicid="9738" href="/z/d/drug information/9738.html" rel="external">
          pancuronium
         </a>
         ) have a slower onset than SCh but are often selected for elective intubation to avoid the side effects of SCh if the patient does not need RSII and does not have a potentially difficult airway  (
         <a class="graphic graphic_table graphicRef114271" href="/z/d/graphic/114271.html" rel="external">
          table 8
         </a>
         ).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          For supraglottic airway insertion
         </strong>
         – Occasionally, a small dose of an NMBA is employed to facilitate supraglottic airway (SGA) placement by preventing coughing and other airway responses. (See
         <a class="local">
          'Induction with supraglottic airway placement'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2986651352">
         <span class="h1">
          VASOPRESSOR AGENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Vasopressor agents may be administered to treat hypotension during induction of general anesthesia. Typical choices of agents are  (
         <a class="graphic graphic_table graphicRef119747" href="/z/d/graphic/119747.html" rel="external">
          table 3
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/141346.html" rel="external">
          "Intraoperative use of vasoactive agents", section on 'Vasopressor and positive inotropic agents'
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          Phenylephrine
         </a>
         , a pure alpha
         <sub>
          1
         </sub>
         -adrenergic agonist that causes both arterial and venous vasoconstriction. Administration of phenylephrine 40 to 100 mcg IV bolus increases blood pressure (BP). Doses may be repeated if necessary.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          Ephedrine
         </a>
         , an alpha and beta receptor adrenergic agonist that causes release of endogenous
         <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">
          norepinephrine
         </a>
         stores. Administration of ephedrine 5 to 10 mg IV bolus increases both BP and heart rate (HR). Doses may be repeated if necessary.
        </p>
        <p>
        </p>
        <p>
         Occasionally, continuous infusion of a
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          phenylephrine
         </a>
         or a more potent vasopressor (eg,
         <a class="drug drug_general" data-topicid="9709" href="/z/d/drug information/9709.html" rel="external">
          norepinephrine
         </a>
         ) may be necessary to maintain hemodynamic stability during and immediately after induction of general anesthesia.
        </p>
        <p class="headingAnchor" id="H3152925089">
         <span class="h1">
          CLINICAL CASE EXAMPLES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patient-specific or procedure-specific considerations may affect selection of anesthetic induction techniques and agents. The following clinical examples are discussed in detail in separate topics:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Hemodynamically unstable patient
         </strong>
         – In a patient with actual or potential hemodynamic instability (eg due to hypovolemia, vasodilation, or severe myocardial dysfunction) (see
         <a class="medical medical_review" href="/z/d/html/94164.html" rel="external">
          "Intraoperative management of shock in adults"
         </a>
         ), we typically select
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          etomidate
         </a>
         (0.2 to 0.4 mg/kg) or
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         (0.5 to 2 mg/kg) to induce general anesthesia [
         <a href="#rid27">
          27
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Need for rapid sequence induction and endotracheal intubation
         </strong>
         – In a patient with high risk for pulmonary aspiration, rapid sequence induction and intubation (RSII) is typically selected to minimize the time the patient is sedated with an unprotected airway. A single rapid bolus of the sedative-hypnotic agent is immediately followed by administration of the neuromuscular blocking agent (NMBA). Underdosing either the sedative-hypnotic or the NMBA may result in laryngospasm if intubation is not successful on first attempt or patient recall. Notably additional adjuvant agents (eg, opioids,
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         ) are usually minimized or avoided for a RSII technique. (See
         <a class="medical medical_review" href="/z/d/html/94214.html" rel="external">
          "Rapid sequence induction and intubation (RSII) for anesthesia"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In some patients with very high risk for aspiration, awake intubation is performed rather than RSII, particularly if a potentially difficult airway is anticipated. (See
         <a class="medical medical_review" href="/z/d/html/90615.html" rel="external">
          "Management of the difficult airway for general anesthesia in adults", section on 'Awake intubation'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Older patient
         </strong>
         – In general, doses of intravenous and inhalation induction agents should be reduced in an older adult. (See
         <a class="medical medical_review" href="/z/d/html/14931.html" rel="external">
          "Anesthesia for the older adult", section on 'Selection and dosing of anesthetic agents'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patients with specific comorbidities
         </strong>
         :
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Heart disease
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/90616.html" rel="external">
          "Anesthesia for noncardiac surgery in patients with ischemic heart disease", section on 'Induction'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/91654.html" rel="external">
          "Intraoperative management for noncardiac surgery in patients with heart failure", section on 'Induction'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          End stage renal disease
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/94254.html" rel="external">
          "Anesthesia for dialysis patients", section on 'Induction'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Brain tumor or head injury
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/93391.html" rel="external">
          "Anesthesia for craniotomy in adults", section on 'Induction of anesthesia'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/94283.html" rel="external">
          "Anesthesia for patients with acute traumatic brain injury", section on 'Choice of anesthetic agents'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Eye injury
         </strong>
         – (See
         <a class="medical medical_review" href="/z/d/html/96505.html" rel="external">
          "Anesthesia for emergency eye surgery", section on 'Choice of induction and adjuvant anesthetic agents'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H888004209">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Definition of general anesthesia
         </strong>
         –
         <strong>
         </strong>
         General anesthesia is a reversible state that includes hypnosis, amnesia, analgesia, akinesia, and autonomic and sensory block such that the patient will not respond to voice or to noxious surgical stimuli. During induction of general anesthesia, sedation progresses as a continuum of effect rather than as a consecutive series of distinct states with clear transitions  (
         <a class="graphic graphic_figure graphicRef113985" href="/z/d/graphic/113985.html" rel="external">
          figure 1
         </a>
         and
         <a class="graphic graphic_table graphicRef109909" href="/z/d/graphic/109909.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Continuum of sedation during anesthetic induction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preparations for induction
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Before patient arrival
         </strong>
         – Anesthesia machine checkout procedure  (
         <a class="graphic graphic_table graphicRef101563" href="/z/d/graphic/101563.html" rel="external">
          table 2
         </a>
         ), preparation for advanced airway management, and preparation of routinely administered drugs. (See
         <a class="local">
          'Before patient arrival'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          After patient arrival
         </strong>
         – Connection of standard American Society of Anesthesiologists (ASA) monitors, establishment of intravenous (IV) access, completion of preprocedure checklist  (
         <a class="graphic graphic_table graphicRef52392" href="/z/d/graphic/52392.html" rel="external">
          table 5
         </a>
         ). (See
         <a class="local">
          'After patient arrival'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Immediately before induction
         </strong>
         – Head positioning in the sniffing position, preoxygenation using 100 percent oxygen. (See
         <a class="local">
          'Immediately before induction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Intravenous anesthetic induction
         </strong>
         –
         <strong>
         </strong>
         Most adults prefer induction with IV agents. Combinations of agents from different pharmacologic classes are typically administered to minimize dose of each anesthetic agent (see
         <a class="local">
          'Intravenous anesthetic induction'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Sedative-hypnotic agent (eg,
         <a class="drug drug_general" data-topicid="9826" href="/z/d/drug information/9826.html" rel="external">
          propofol
         </a>
         ,
         <a class="drug drug_general" data-topicid="8428" href="/z/d/drug information/8428.html" rel="external">
          etomidate
         </a>
         ,
         <a class="drug drug_general" data-topicid="8588" href="/z/d/drug information/8588.html" rel="external">
          ketamine
         </a>
         )  (
         <a class="graphic graphic_table graphicRef102350" href="/z/d/graphic/102350.html" rel="external">
          table 6
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Adjuvant agent(s) (eg, short-acting opioid,
         <a class="drug drug_general" data-topicid="9558" href="/z/d/drug information/9558.html" rel="external">
          lidocaine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9650" href="/z/d/drug information/9650.html" rel="external">
          midazolam
         </a>
         )  (
         <a class="graphic graphic_table graphicRef106541" href="/z/d/graphic/106541.html" rel="external">
          table 7
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Neuromuscular blocking agent (NMBA) if endotracheal intubation is planned or to facilitate supraglottic airway placement  (
         <a class="graphic graphic_table graphicRef114271" href="/z/d/graphic/114271.html" rel="external">
          table 8
         </a>
         ) (see
         <a class="local">
          'Neuromuscular blocking agents'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Inhalation anesthetic agent(s), often added shortly after achieving initial loss of consciousness
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Inhalation anesthetic induction
         </strong>
         –
         <strong>
         </strong>
         Inhalation induction is often preferred by children due to fear of needles, and may be selected for adults when spontaneous breathing during induction is desirable. Agents include the potent volatile anesthetics (eg,
         <a class="drug drug_general" data-topicid="8992" href="/z/d/drug information/8992.html" rel="external">
          isoflurane
         </a>
         ,
         <a class="drug drug_general" data-topicid="9887" href="/z/d/drug information/9887.html" rel="external">
          sevoflurane
         </a>
         ,
         <a class="drug drug_general" data-topicid="8891" href="/z/d/drug information/8891.html" rel="external">
          desflurane
         </a>
         ) and the gas
         <a class="drug drug_general" data-topicid="10086" href="/z/d/drug information/10086.html" rel="external">
          nitrous oxide
         </a>
         (
         <a class="graphic graphic_table graphicRef113972" href="/z/d/graphic/113972.html" rel="external">
          table 9
         </a>
         ). (See
         <a class="local">
          'Inhalation anesthetic induction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Use of vasopressor agents
         </strong>
         –
         <strong>
         </strong>
         <a class="drug drug_general" data-topicid="9768" href="/z/d/drug information/9768.html" rel="external">
          Phenylephrine
         </a>
         or
         <a class="drug drug_general" data-topicid="9114" href="/z/d/drug information/9114.html" rel="external">
          ephedrine
         </a>
         may be administered if necessary to treat hypotension. (See
         <a class="local">
          'Vasopressor agents'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Patient-specific and procedure-specific considerations
         </strong>
         – (See
         <a class="local">
          'Clinical case examples'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1461154560">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Liza M Weavind, MBBCh, FCCM, MMHC, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          ASA Continuum of Depth of Sedation: Definition of General Anesthesia and Levels of Sedation/Analgesia. Committee of Origin: Quality Management and Departmental Administration, 2009. https://www.asahq.org/standards-and-guidelines/continuum-of-depth-of-sedation-definition-of-general-anesthesia-and-levels-of-sedationanalgesia.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sepúlveda PO, Tapia LF, Monsalves S. Neural inertia and differences between loss of and recovery from consciousness during total intravenous anaesthesia: a narrative review. Anaesthesia 2019; 74:801.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Friedman EB, Sun Y, Moore JT, et al. A conserved behavioral state barrier impedes transitions between anesthetic-induced unconsciousness and wakefulness: evidence for neural inertia. PLoS One 2010; 5:e11903.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moppett IK, Shorrock ST. Working out wrong-side blocks. Anaesthesia 2018; 73:407.
          </a>
         </li>
         <li class="breakAll">
          https://www.asahq.org/For-Members/Clinical-Information/2008-ASA-Recommendations-for-PreAnesthesia-Checkout.aspx.
         </li>
         <li class="breakAll">
          American Society of Anesthesiologists. Standards for Basic Anesthetic Monitoring. www.asahq.org/Search.aspx?q=standards+basic+anesthetic+monitoring (Accessed on March 29, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kobayashi M, Ayuse T, Hoshino Y, et al. Effect of head elevation on passive upper airway collapsibility in normal subjects during propofol anesthesia. Anesthesiology 2011; 115:273.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tanoubi I, Drolet P, Donati F. Optimizing preoxygenation in adults. Can J Anaesth 2009; 56:449.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nimmagadda U, Salem MR, Crystal GJ. Preoxygenation: Physiologic Basis, Benefits, and Potential Risks. Anesth Analg 2017; 124:507.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thwaites A, Edmends S, Smith I. Inhalation induction with sevoflurane: a double-blind comparison with propofol. Br J Anaesth 1997; 78:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joshi GP. Inhalational techniques in ambulatory anesthesia. Anesthesiol Clin North America 2003; 21:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suzuki KS, Oohata M, Mori N. Multiple-deep-breath inhalation induction with 5% sevoflurane and 67% nitrous oxide: comparison with intravenous injection of propofol. J Anesth 2002; 16:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xing J, Liang L, Zhou S, et al. Intravenous Lidocaine Alleviates the Pain of Propofol Injection by Local Anesthetic and Central Analgesic Effects. Pain Med 2018; 19:598.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sigston PE, Jenkins AM, Jackson EA, et al. Rapid inhalation induction in children: 8% sevoflurane compared with 5% halothane. Br J Anaesth 1997; 78:362.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lejus C, Bazin V, Fernandez M, et al. Inhalation induction using sevoflurane in children: the single-breath vital capacity technique compared to the tidal volume technique*. Anaesthesia 2006; 61:535.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Joo HS, Perks WJ. Sevoflurane versus propofol for anesthetic induction: a meta-analysis. Anesth Analg 2000; 91:213.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White PF, Tang J, Wender RH, et al. Desflurane versus sevoflurane for maintenance of outpatient anesthesia: the effect on early versus late recovery and perioperative coughing. Anesth Analg 2009; 109:387.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mostafa SM, Atherton AM. Sevoflurane for difficult tracheal intubation. Br J Anaesth 1997; 79:392.
          </a>
         </li>
         <li class="breakAll">
          Thomas Ebert and Larry Lindenbaum. Inhaled Anesthetics. In: Clinical Anesthesia, Seventh, Paul G. Barash (Ed), Lippincott Williams Wilkins, Philadelphia 2013. p.447-477.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boonmak P, Boonmak S, Pattanittum P. High initial concentration versus low initial concentration sevoflurane for inhalational induction of anaesthesia. Cochrane Database Syst Rev 2016; :CD006837.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Oliveira GS Jr, Girao W, Fitzgerald PC, McCarthy RJ. The effect of sevoflurane versus desflurane on the incidence of upper respiratory morbidity in patients undergoing general anesthesia with a Laryngeal Mask Airway: a meta-analysis of randomized controlled trials. J Clin Anesth 2013; 25:452.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torri G. Inhalation anesthetics: a review. Minerva Anestesiol 2010; 76:215.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sun R, Jia WQ, Zhang P, et al. Nitrous oxide-based techniques versus nitrous oxide-free techniques for general anaesthesia. Cochrane Database Syst Rev 2015; :CD008984.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Myles PS, Chan MT, Kasza J, et al. Severe Nausea and Vomiting in the Evaluation of Nitrous Oxide in the Gas Mixture for Anesthesia II Trial. Anesthesiology 2016; 124:1032.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Boer HD, Driessen JJ, Marcus MA, et al. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study. Anesthesiology 2007; 107:239.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pühringer FK, Rex C, Sielenkämper AW, et al. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology 2008; 109:188.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jabre P, Combes X, Lapostolle F, et al. Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. Lancet 2009; 374:293.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 94135 Version 48.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://www.asahq.org/standards-and-guidelines/continuum-of-depth-of-sedation-definition-of-general-anesthesia-and-levels-of-sedationanalgesia" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : ASA Continuum of Depth of Sedation: Definition of General Anesthesia and Levels of Sedation/Analgesia. Committee of Origin: Quality Management and Departmental Administration, 2009. https://www.asahq.org/standards-and-guidelines/continuum-of-depth-of-sedation-definition-of-general-anesthesia-and-levels-of-sedationanalgesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30835820" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Neural inertia and differences between loss of and recovery from consciousness during total intravenous anaesthesia: a narrative review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20689589" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : A conserved behavioral state barrier impedes transitions between anesthetic-induced unconsciousness and wakefulness: evidence for neural inertia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29280144" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Working out wrong-side blocks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29280144" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Working out wrong-side blocks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29280144" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Working out wrong-side blocks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21701378" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Effect of head elevation on passive upper airway collapsibility in normal subjects during propofol anesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19399574" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Optimizing preoxygenation in adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28099321" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Preoxygenation: Physiologic Basis, Benefits, and Potential Risks.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9135350" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Inhalation induction with sevoflurane: a double-blind comparison with propofol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12812394" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Inhalational techniques in ambulatory anesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14517657" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Multiple-deep-breath inhalation induction with 5% sevoflurane and 67% nitrous oxide: comparison with intravenous injection of propofol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28525614" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Intravenous Lidocaine Alleviates the Pain of Propofol Injection by Local Anesthetic and Central Analgesic Effects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9135351" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Rapid inhalation induction in children: 8% sevoflurane compared with 5% halothane.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16704586" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Inhalation induction using sevoflurane in children: the single-breath vital capacity technique compared to the tidal volume technique*.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10866915" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Sevoflurane versus propofol for anesthetic induction: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19608808" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Desflurane versus sevoflurane for maintenance of outpatient anesthesia: the effect on early versus late recovery and perioperative coughing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9389864" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Sevoflurane for difficult tracheal intubation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9389864" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Sevoflurane for difficult tracheal intubation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27356171" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : High initial concentration versus low initial concentration sevoflurane for inhalational induction of anaesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23965188" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : The effect of sevoflurane versus desflurane on the incidence of upper respiratory morbidity in patients undergoing general anesthesia with a Laryngeal Mask Airway: a meta-analysis of randomized controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20203550" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Inhalation anesthetics: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26545294" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Nitrous oxide-based techniques versus nitrous oxide-free techniques for general anaesthesia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26904965" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Severe Nausea and Vomiting in the Evaluation of Nitrous Oxide in the Gas Mixture for Anesthesia II Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17667567" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18648227" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19573904" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
